# Valaciclovir Hydrochloride Phase III for Hematopoietic Stem Cell Transplantation Patients

> **NCT01602562** · PHASE3 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 40 (actual)

## Conditions studied

- Herpes Simplex

## Interventions

- **DRUG:** VACV tablets (Adults or pediatrics) or granules (pediatrics)

## Key facts

- **NCT ID:** NCT01602562
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-05-07
- **Primary completion:** 2013-05-01
- **Final completion:** 2013-05-24
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2018-08-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01602562

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01602562, "Valaciclovir Hydrochloride Phase III for Hematopoietic Stem Cell Transplantation Patients". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01602562. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*